Compare Alcon AG (ALC) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs NetEase Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while NetEase Inc trades at $133.85 (market cap $83.83B). The key difference: NetEase Inc is far larger — about 2.6× Alcon AG's market cap, and NetEase Inc pays the higher dividend (2.31%). Which is the better fit depends on your goals.
| ALC | NTES | |
|---|---|---|
Market Cap | $32.69B | $83.83B |
Sector | Health | Media |
52-Week High | $92.22 | $159.34 |
52-Week Low | $62.02 | $109.26 |
Enterprise Value | $36.28B | $60.31B |
Dividend Yield | 0.54% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
NetEase (NTES) trades at $130.82, up 2.81% today, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings that beat estimates, with revenue growth to $112.63B in 2025 and a net income margin of 29.84%. Recent news highlights international expansion and a $0.72 dividend payment scheduled for June 2026.
The stock presents a compelling value with a P/E of 16.83 and robust profitability metrics. Analyst consensus is strongly bullish with 82% buy ratings and a 34.7% upside potential. Key risks include reliance on the Chinese market and competitive pressures in gaming. Cash flow trends show volatility, but the balance sheet remains strong with $137.58B in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
